NAVIGATOR Trial

The NAVIGATOR trial was a large clinical study that tested whether a medication called navitoclax could help reduce the risk of blood clots, blood vessel blockages, and related health problems in people with certain blood disorders, such as myelofibrosis or other myeloproliferative neoplasms. Participants received navitoclax or a placebo, and researchers monitored outcomes to see if the drug improved blood health and prevented complications. The goal was to evaluate the safety and effectiveness of navitoclax as a treatment option for these conditions.